Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 1
2005 2
2006 1
2007 4
2008 1
2010 2
2011 1
2017 1
2019 3
2020 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, Plummer R, Jones RH, Nielsen D, Windfeld K, Ghatta S, Slomovitz BM, Spicer JF, Yachnin J, Ang JE, Mau-Sørensen PM, Forster MD, Collins D, Dean E, Rangwala RA, Lassen U. de Bono JS, et al. Among authors: thistlethwaite fc. Lancet Oncol. 2019 Mar;20(3):383-393. doi: 10.1016/S1470-2045(18)30859-3. Epub 2019 Feb 8. Lancet Oncol. 2019. PMID: 30745090 Clinical Trial.
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau HT, Machiels JP, Spicer JF, Jones R, Forster MD, Cornez N, Gennigens C, Johnson ML, Thistlethwaite FC, Rangwala RA, Ghatta S, Windfeld K, Harris JR, Lassen UN, Coleman RL. Hong DS, et al. Among authors: thistlethwaite fc. Clin Cancer Res. 2020 Mar 15;26(6):1220-1228. doi: 10.1158/1078-0432.CCR-19-2962. Epub 2019 Dec 3. Clin Cancer Res. 2020. PMID: 31796521 Clinical Trial.
Engineering T cells for cancer therapy.
Mansoor W, Gilham DE, Thistlethwaite FC, Hawkins RE. Mansoor W, et al. Among authors: thistlethwaite fc. Br J Cancer. 2005 Nov 14;93(10):1085-91. doi: 10.1038/sj.bjc.6602839. Br J Cancer. 2005. PMID: 16251873 Free PMC article. Review.
EPIC: an evaluation of the psychological impact of early-phase clinical trials in cancer patients.
Jittla P, Graham DM, Zhou C, Halliwell J, O'Reilly S, Aruketty S, Azizi A, Germetaki T, Lowe J, Little M, Punnett G, McMahon P, Benson L, Carter L, Krebs MG, Thistlethwaite FC, Darlington E, Yorke J, Cook N. Jittla P, et al. Among authors: thistlethwaite fc. ESMO Open. 2022 Oct;7(5):100550. doi: 10.1016/j.esmoop.2022.100550. Epub 2022 Aug 19. ESMO Open. 2022. PMID: 35994790 Free PMC article.
Involvement of Brca2 in DNA repair.
Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, Colledge WH, Friedman LS, Ponder BA, Venkitaraman AR. Patel KJ, et al. Among authors: thistlethwaite fc. Mol Cell. 1998 Feb;1(3):347-57. doi: 10.1016/s1097-2765(00)80035-0. Mol Cell. 1998. PMID: 9660919 Free article.
Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma.
Pillai M, Jiang Y, Lorigan PC, Thistlethwaite FC, Thomas M, Kirillova N, Bridgeman JS, Kueberuwa G, Biswas S, Velazquez P, Chonzi D, Guest RD, Roberts ZJ, Hawkins RE. Pillai M, et al. Among authors: thistlethwaite fc. Am J Cancer Res. 2022 Aug 15;12(8):3967-3984. eCollection 2022. Am J Cancer Res. 2022. PMID: 36119832 Free PMC article.
Thymic lymphomas in mice with a truncating mutation in Brca2.
Friedman LS, Thistlethwaite FC, Patel KJ, Yu VP, Lee H, Venkitaraman AR, Abel KJ, Carlton MB, Hunter SM, Colledge WH, Evans MJ, Ponder BA. Friedman LS, et al. Among authors: thistlethwaite fc. Cancer Res. 1998 Apr 1;58(7):1338-43. Cancer Res. 1998. PMID: 9537225
18 results